Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

被引：0
|
作者：
Jian Zhang
Nicholas P. McAndrew
Xiaojia Wang
Yiqun Du
Brian DiCarlo
Mei Wang
Kan Chen
Wenlei Yu
Xichun Hu
机构：
[1] Fudan University Shanghai Cancer Center,Phase I Clinical Trial Center
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] UCLA David Geffen School of Medicine,Division of Hematology/Oncology
[4] Zhejiang Cancer Hospital,Department of Medical Oncology
[5] Dizal Pharmaceutical,undefined
[6] Fudan University Shanghai Cancer Center,undefined
来源：
Breast Cancer Research | / 25卷
关键词：
HER2; Tyrosine kinase inhibitor; Blood–brain barrier; Breast cancer; Central nervous system metastases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 28 条
  • [1] Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor
    Zhang, Jian
    McAndrew, Nicholas P.
    Wang, Xiaojia
    Du, Yiqun
    DiCarlo, Brian
    Wang, Mei
    Chen, Kan
    Yu, Wenlei
    Hu, Xichun
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [2] Preclinical and early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer
    Zhang, Jian
    McAndrew, Nicholas
    Yu, Wenlei
    Pan, Xiaomei
    Wang, Mei
    Hu, Xichun
    CANCER RESEARCH, 2022, 82 (04)
  • [3] Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer
    Zhang, J.
    McAndrew, N.
    Yu, W.
    Pan, X.
    Hu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S646
  • [4] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
    McAndrew, Nicholas P.
    Hu, Xichun
    Zhang, Jian
    Wang, Xiaojia
    Yu, Wenlei
    Pan, Xiaomei
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer.
    Hu, Xichun
    Zhang, Jian
    McAndrew, Nicholas Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations
    Sun, Yuting
    Andrews, Kristin L.
    Tangpeerachaikul, Anupong
    Nguyen, Tuan M.
    Gerard, Baudouin
    Kohl, Nancy E.
    Horan, Joshua C.
    Pelish, Henry E.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] KD019: Blood brain barrier penetrant HER2/neu, Src, and EGFR inhibitor
    Tonra, James R.
    Poyurovsky, Masha
    Liu, Kevin G.
    Patel, Jeegar
    Rao, Nishta
    Tilton, Robert
    Ryan, John L.
    Berger, Mark S.
    Witte, Larry
    Kim, Ji-In
    Waksal, Samuel D.
    CANCER RESEARCH, 2015, 75
  • [8] NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models
    Andrews, K. L.
    Sun, Y.
    Gerard, B.
    Tangpeerachaikul, A.
    Mente, S.
    Kemper, R. A.
    Martin, C. M.
    Kohl, N. E.
    Horan, J. C.
    Pelish, H. E.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S76 - S77
  • [9] The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer
    O'Brien, N. A.
    Conklin, D.
    McDermott, M.
    Luo, T.
    Ayala, R.
    Issakhanian, S.
    Salgar, S.
    Hurvitz, S.
    Slamon, D. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
    Helal, Christopher J.
    Arnold, Eric
    Boyden, Tracey
    Chang, Cheng
    Chappie, Thomas A.
    Fisher, Ethan
    Hajos, Mihaly
    Harms, John F.
    Hoffman, William E.
    Humphrey, John M.
    Pandit, Jayvardhan
    Kang, Zhijun
    Kleiman, Robin J.
    Kormos, Bethany L.
    Lee, Che-Wah
    Lun, Jiemin
    Maldad, Noha
    McDowell, Laura
    McGinnis, Dina
    O'Connor, Rebecca E.
    O'Donnell, Christopher J.
    Ogden, Adam
    Piotrowski, Mary
    Schmidt, Christopher J.
    Seymour, Patricia A.
    Ueno, Hirokazu
    Vansell, Nichole
    Verhoest, Patrick R.
    Yang, Edward X.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (03) : 1001 - 1018
123